These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 20632973)

  • 1. Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration.
    Cadet JL; Jayanthi S; McCoy MT; Beauvais G; Cai NS
    CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):526-38. PubMed ID: 20632973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diversity of dopamine receptors: new molecular and pharmacological developments.
    Hartman DS; Lanau F
    Pol J Pharmacol; 1997 Aug; 49(4):191-9. PubMed ID: 9437762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity.
    Centonze D; Grande C; Saulle E; Martin AB; Gubellini P; Pavón N; Pisani A; Bernardi G; Moratalla R; Calabresi P
    J Neurosci; 2003 Sep; 23(24):8506-12. PubMed ID: 13679419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation.
    Wersinger C; Chen J; Sidhu A
    Mol Cell Neurosci; 2004 Jan; 25(1):124-37. PubMed ID: 14962746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine acting at D1-like, D2-like and α1-adrenergic receptors differentially modulates theta and gamma oscillatory activity in primary motor cortex.
    Özkan M; Johnson NW; Sehirli US; Woodhall GL; Stanford IM
    PLoS One; 2017; 12(7):e0181633. PubMed ID: 28732063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D1 and D2 receptor-mediated dopaminergic modulation of visual responses in cat dorsal lateral geniculate nucleus.
    Zhao Y; Kerscher N; Eysel U; Funke K
    J Physiol; 2002 Feb; 539(Pt 1):223-38. PubMed ID: 11850515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coactivation of D1 and D2 dopamine receptors is required for long-term synaptic depression in the striatum.
    Calabresi P; Maj R; Mercuri NB; Bernardi G
    Neurosci Lett; 1992 Aug; 142(1):95-9. PubMed ID: 1357611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine Receptors and Neurodegeneration.
    Rangel-Barajas C; Coronel I; Florán B
    Aging Dis; 2015 Sep; 6(5):349-68. PubMed ID: 26425390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of D1- or D2-receptors in drug-naive rats with different degrees of unilateral nigro-striatal dopamine lesions.
    Fornaguera J; Huston JP; Carey RJ; Schwarting RK
    Psychopharmacology (Berl); 1995 May; 119(2):145-54. PubMed ID: 7659761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine receptor regulation of Ca2+ levels in individual isolated nerve terminals from rat striatum: comparison of presynaptic D1-like and D2-like receptors.
    Wu J; Dougherty JJ; Nichols RA
    J Neurochem; 2006 Jul; 98(2):481-94. PubMed ID: 16805841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
    LaHoste GJ; Marshall JF
    Behav Brain Res; 1990 May; 38(3):233-42. PubMed ID: 1973041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
    Mishra A; Singh S; Tiwari V; Bano S; Shukla S
    Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions.
    Taymans JM; Leysen JE; Langlois X
    J Neurochem; 2003 Mar; 84(5):1118-27. PubMed ID: 12603835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment.
    Smith TS; Trimmer PA; Khan SM; Tinklepaugh DL; Bennett JP
    Brain Res; 1997 Aug; 765(2):189-97. PubMed ID: 9313891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
    Lindgren HS; Ohlin KE; Cenci MA
    Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reserpine increases Fos activity in the rat basal ganglia via a quinpirole-sensitive mechanism.
    Cole DG; Di Figlia M
    Neuroscience; 1994 May; 60(1):115-23. PubMed ID: 7914358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
    Paul ML; Graybiel AM; David JC; Robertson HA
    J Neurosci; 1992 Oct; 12(10):3729-42. PubMed ID: 1357113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic treatment weakens medium spiny neuron collateral inhibition in the parkinsonian striatum.
    Wei W; Ding S; Zhou FM
    J Neurophysiol; 2017 Mar; 117(3):987-999. PubMed ID: 27927785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine-induced functional activation of Gα
    Odagaki Y; Kinoshita M; Ota T
    J Recept Signal Transduct Res; 2019 Feb; 39(1):9-17. PubMed ID: 31223051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.